



# MONO PHARMACARE LIMITED

CIN:U24304GJ2022PLC136193

GST NO.: 24AAQCM2821E1ZN

November 14, 2023

To,  
National Stock Exchange of India Ltd.  
Exchange Plaza,  
Plot no. C/1, G Block,  
Bandra-Kurla Complex,  
Bandra (E) Mumbai - 400 051  
Ph: (022)-26598100-8114

**Script Symbol: MONOPHARMA**  
**NSE ISIN No.: INE00IPO1012**

**Subject: Outcome of Board Meeting Held on 14<sup>th</sup> November, 2023.**

Dear Sir,

We would like to inform the Exchange that, Meeting of Board of Directors was held at registered office of the company situated at 1A, Krinkal Apartment, Opp. Mahalaxmi Temple, Paldi, Ahmedabad, Gujarat: 380007 on today, i.e., Tuesday, November 14, 2023 and the Board of Directors, inter alia, approved the un-audited financial results of the Company for the quarter and half year ended September 30, 2023 along with Cash Flow Statement of the Company for the half year ended September 30, 2023.

The un-audited financial results of the Company for the half year ended on September 30, 2023 is enclosed along with the Limited Review Report issued by M/s. Kumbhat & Co. Chartered Accountants, Statutory Auditor of the Company. The meeting of the Board of Directors commenced at 11.30 a.m. and concluded at 04.30 p.m.

We request you to kindly take it on your record, under Regulation 33 of the SEBI (LODR) Regulations, 2015.

Thanking you,

**For Mono Pharmacare Limited**

**Managing Director**

---

## **Limited Review Report**

Review Report to  
The Board of Directors,  
**MONO PHARMACARE LIMITED**

We have reviewed the accompanying Statement of Standalone Unaudited Financial Results ('the Statement') of **MONO PHARMACARE LIMITED** ("the Company") for the half year ended September 30, 2023, prepared and being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The preparation of the Statement is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement of Unaudited Financial Results based on our review.

We conducted our review in accordance with the Standard on Review Engagement-(SRE) 2410, on "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognised accounting practices and policies generally accepted in India, has not disclosed the information

**KUMBHAT & CO**  
Chartered Accountants

---

required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Place:** Mumbai  
**Dated:** Nov. 14, 2023

**For KUMBHAT & CO.**  
*Chartered Accountants*  
Firm Regn. No. 001609S

Gaurang Champaklal Unadkat  
Digitally signed by Gaurang Champaklal Unadkat  
Date: 2023.11.14 12:15:17 +05'30'

**Gaurang C. Unadkat**  
Partner  
Mem.No. 131708

UDIN: **23131708BGWHHZ1608**

**MONO PHARMACARE LIMITED**

Registered Office: 1A, Krinkal Apartment, Opp. Mahalaxmi Temple, Paldi, Ahmedabad, Gujarat, Pin-380007

CIN: U24304GJ2022PLC136193

Website: www.monopharmacareltd.com

Email: info@monopharmacareltd.com


**Standalone Statement of Assets and Liabilities**

(Rupees in Lakhs)

	Particulars	(Rupees in Lakhs)		
		As at September 30, 2023	As at 31st March, 2023	As at 31st March, 2022
<b>A.</b>	<b>EQUITY AND LIABILITIES</b>			
(1)	<b>Shareholders' Funds</b>			
	(a) Share Capital	1766.86	1,236.86	427.57
	(b) Reserve and surplus	987.35	103.06	-
		<b>2754.20</b>	<b>1,339.92</b>	<b>427.57</b>
(2)	<b>Non-current liabilities</b>			
	(a) Long-term borrowings	355.55	343.48	151.37
		<b>355.55</b>	<b>343.48</b>	<b>151.37</b>
(3)	<b>Current Liabilities</b>			
	(a) Short Term Borrowings	735.54	907.05	492.56
	(b) Trade Payables	295.17	209.33	334.60
	(c) Other Current Liabilities	45.88	61.94	5.82
	(d) Short-term Provisions	71.36	44.85	26.40
		<b>1147.95</b>	<b>1,223.16</b>	<b>859.36</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>			
		<b>4257.71</b>	<b>2,906.56</b>	<b>1,438.31</b>
<b>B.</b>	<b>ASSETS</b>			
(1)	<b>Non Current Assets</b>			
	(a) Property, Plants & Equipment			
	(i) Tangible Assets	16.69	19.16	29.68
	(b) Non-Current Investments	273.08	196.55	-
	(c) Deferred tax assets (Net)	9.85	5.09	-
	(d) Long-term loans and advances	1.45	1.45	-
		<b>301.07</b>	<b>222.25</b>	<b>29.68</b>
(2)	<b>Current Assets</b>			
	(a) Inventories	1968.84	1,518.12	471.37
	(b) Trade Receivables	1555.32	808.39	552.10
	(c) Cash and Cash Equivalents	146.22	22.86	24.47
	(d) Short Term Loans and Advances	204.93	308.67	358.34
	(e) Other Current Assets	81.32	26.27	2.35
		<b>3956.64</b>	<b>2,684.31</b>	<b>1,408.63</b>
	<b>TOTAL ASSETS</b>	<b>4257.71</b>	<b>2,906.56</b>	<b>1,438.31</b>

For and on behalf of the Board of Directors  
Mono Pharmacare Limited


Panilam S. Lakhatariya  
Chairman & Managing Director  
DIN: 07659275



Date: November 14, 2023

Ahmedabad

**MONO PHARMACARE LIMITED**

Registered Office: 1A, Krinkal Apartment, Opp. Mahalaxmi Temple, Paldi, Ahmedabad, Gujarat, Pin-380007

CIN: U24304GJ2022PLC136193

Website: www.monopharmacareLtd.com

Email: info@monopharmacareLtd.com

**Statement of Unaudited Standalone Financial Results for the Half Year ended on September 30, 2023**

		(Rupees in Lakhs)				
	Particulars	For the Half Year Ended			Year Ended	
		September 30, 2023	March 31, 2023	September 30, 2022	March 31, 2023	March 31, 2022
		(Unaudited)	(Audited)	Refer Note No. 4	Refer Note No. 4	(Audited)
<b>I</b>	Revenue from operation	3459.87	2195.55	2344.65	4540.20	3698.30
<b>II</b>	Other income	77.84	19.01	6.73	25.73	11.96
<b>III</b>	<b>Total Revenue ( I + II )</b>	<b>3537.71</b>	<b>2214.56</b>	<b>2351.38</b>	<b>4565.94</b>	<b>3710.26</b>
<b>IV</b>	<b>Expenses</b>					
	Purchase of Traded Goods	3546.65	2749.73	2415.85	5165.58	3526.46
	(Increase)/Decrease in Stock	-450.72	-829.00	-217.76	-1046.75	-57.32
	Employee Benefits Expenses	105.65	69.51	22.25	91.76	62.18
	Finance Cost	57.64	55.95	36.98	92.93	74.21
	Depreciation and Amortisation Cost	3.75	4.48	3.39	7.88	10.82
	Other expenses	54.68	71.54	26.16	97.70	38.83
	<b>Total Expenses</b>	<b>3317.64</b>	<b>2122.22</b>	<b>2286.87</b>	<b>4409.09</b>	<b>3655.18</b>
	<b>Profit before tax Extraordinary and Exceptional Items ( III - IV )</b>	<b>220.07</b>	<b>92.34</b>	<b>64.51</b>	<b>156.85</b>	<b>55.09</b>
<b>VI</b>	Exceptional Items	0.00	0.00		0.00	0.00
<b>VII</b>	<b>Extraordinary Items And Tax ( V- VI )</b>					
	Prior Period Expenses	0.00	0.00	0	0.00	0.00
<b>VIII</b>	<b>Profit Before Tax</b>	<b>220.07</b>	<b>92.34</b>	<b>64.51</b>	<b>156.85</b>	<b>55.09</b>
<b>IX</b>	Tax Expenses					
	(1) Current Tax	38.30	33.74	5.00	38.74	20.00
	(2) Deferred Tax	-4.76	-5.28	-	-5.28	
<b>X</b>	<b>Profit (Loss) for the Period</b>	<b>186.54</b>	<b>63.88</b>	<b>59.51</b>	<b>123.39</b>	<b>35.09</b>
<b>XI</b>	Earning per Equity share :					
	(1) Basic	1.43	0.93	1.28	1.80	0.75
	(2) Diluted	1.43	0.93	1.28	1.80	0.75

**Notes:**

1. The above results were reviewed and recommended by the Audit Committee, at its meeting held on 14th November, 2023 for approval by the Board and these results were approved and taken on record at the meeting of the Board of Directors of the Company held on that date. The Statutory Auditors have expressed an unqualified opinion.

2. The Company is listed on the SME platform of the National Stock Exchange of India Limited and the provisions of the IND AS as per rule 4 of the Companies (Indian Accounting Standards) Rules, 2015, Reconciliation of Profit and Loss and Reconciliation of Equity does not apply to the company and hence not reported.

3. The information presented above is extracted from the Audited Standalone Financial Statements for the financial year ended 31st March, 2023, and are prepared in accordance with the Accounting Standards as issued by the Institute of Chartered Accountants of India and as specified in Section 133 of the Companies Act, 2013 and the relevant rules thereof.

4. The figures for the preceding half year ended on 31st March, 2023 as reported in these financial result, are the balancing figures between audited figures in respect of the full financial year ended on 31st March, 2023 and year to date unaudited figures upto the end of 30th September, 2022 based on the Management Certified Accounts which are not subjected to Limited Review by the Statutory Auditors. The Audited Figures for the year ended March 31, 2023 are derived from Audited Financial Statement of Mono Pharmicare Limited and M/s. Mono Chemist, a partnership firm which was converted in Mono Pharmicare Limited.

5. The company came with an Initial Public Offer of equity shares on 28th Aug., 2023 and closed on August 30, 2023. The initial public offer ("IPO") was for 53,00,000 equity shares of face value of Rs. 10 each at premium of Rs. 18 per share aggregating to INR 1484.00 lakhs. The shares of the company were listed on the National Stock Exchange of India Limited, Emerge Platform on September 7, 2023

6. The details of utilization of IPO Proceeds are as per the table set forth below:


S. No.	Particulars	Planned as per Prospectus (Rs. In Lakhs)	Utilised (Rs. In Lakhs)	Pending to be utilised (Rs. In Lakhs)
1	Working Capital Requirements	898.00	852.34	45.66
2	General Corporate Purpose	366.00	31.20	334.80
3	Issue expenses	220.00	220.00	-
	<b>Total Proceeds from the Issue</b>	<b>1,484.00</b>	<b>1,103.54</b>	<b>380.46</b>

6. The above financial results are available on the website of the company i.e. www.monopharmacareLtd.com and on the website of emerge platform of National Stock Exchange i.e. www.nseindia.com

7. Figures for previous half year/ year have been regrouped wherever necessary.

For and on behalf of the Board of Directors  
Mono Pharmicare Limited

**Panilam S. Lakhatariya**  
Chairman & Managing Director



Date: November 14, 2023  
Ahmedabad


**MONO PHARMACARE LIMITED**

**Cash Flow Statement statement for the period ended on Sept. 30, 2023**

	<b>Sept. 30, 2023</b>	<b>March 31, 2023</b>
	(Rupees in Lakhs)	(Rupees in Lakhs)
<b>Cash flow from operating activities</b>		
<b>Profit/(loss) before tax</b>	<b>220.07</b>	156.85
Non-cash adjustments to reconcile profit before tax to net cash flows		
Depreciation	3.75	7.88
Finance Cost	57.64	92.93
<b>Operating profit/(loss) before working capital changes</b>	<b>281.47</b>	<b>257.66</b>
<b>Movements in working capital:</b>		
Increase/(decrease) in trade payables	85.84	-125.27
Increase/(decrease) in other current liabilities	-16.06	56.12
Increase/(decrease) in short term provision	26.51	18.45
Increase/(decrease) in short term borrowings	-171.51	414.49
Decrease/(increase) in Inventories	-450.72	-1046.75
Decrease/(increase) in trade receivables	-746.93	-256.29
Decrease/(increase) in short-term loans and advances	103.74	49.67
Decrease/(increase) in other Current Assets	-55.05	-23.92
<b>Cash generated from Operations</b>	<b>-942.72</b>	<b>-655.84</b>
Less: Direct taxes paid	-38.30	-38.74
<b>Net Cash from Operating Activities (A)</b>	<b>-981.02</b>	<b>-694.59</b>
<b>Cash flows from investing activities</b>		
Sale/(Purchase) of Fixed Assets	-1.28	-85.46
Purchase of Investment	-76.53	-196.55
<b>Net cash flow from/(used in) investing activities (B)</b>	<b>-77.81</b>	<b>-282.01</b>
<b>Cash flow from financing activities</b>		
Acceptance / (Repayment) of Long Term Loan	12.07	192.11
Payment / (Repayment) of Long term Loan advance	0.00	-1.45
Proceeds from issue of equity shares	530.00	809.29
Increase in Security Premium	697.75	67.97
Finance Cost	-57.64	-92.93
<b>Net cash flow from/(used in) financing activities (C)</b>	<b>1182.18</b>	<b>974.99</b>
Net increase/(decrease) in cash and cash equivalents (A+B+C)	123.35	-1.61
Cash and cash equivalents at the beginning of the year	22.86	24.47
Cash and cash equivalents at the end of the year	146.22	22.86
<b>Net increase/(decrease) in cash and cash equivalents</b>	<b>123.36</b>	<b>-1.61</b>

**For and on behalf of the Board of Directors  
Mono Pharmacare Limited**

*Panilam S. Lakhatariya*  
**Panilam S. Lakhatariya**  
Chairman & Managing Director  
DIN: 07659275



Date: November 14, 2023  
Ahmedabad

## **Limited Review Report**

Review Report to  
The Board of Directors,  
**MONO PHARMACARE LIMITED**

We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results ('the Statement') of **MONO PHARMACARE LIMITED** ("the Parent") ("the Company") and its Subsidiary Company for the half year ended September 30, 2023, prepared and being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The preparation of the Statement is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Consolidated Statement of Unaudited Financial Results based on our review.

We conducted our review in accordance with the Standard on Review Engagement-(SRE) 2410, on "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognised accounting practices

and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Place:** Mumbai  
**Dated:** Nov. 14, 2023

**For KUMBHAT & CO.**  
*Chartered Accountants*  
Firm Regn. No. 001609S

Gaurang Champaklal Unadkat  
Digitally signed by Gaurang  
Champaklal Unadkat  
Date: 2023.11.14 12:14:28  
+05'30'

**Gaurang C. Unadkat**  
Partner  
Mem.No. 131708  
UDIN: **23131708BGWHIB9346**



**MONO PHARMACARE LIMITED**

Registered Office: 1A, Krinkal Apartment, Opp. Mahalaxmi Temple, Paldi, Ahmedabad, Gujarat, Pin-380007

CIN: U24304GJ2022PLC136193

Website: www.monopharmacareltd.com

Email: info@monopharmacareltd.com

**Consolidated Statement of Unaudited Financial Results for the Half Year ended on September 30, 2023****(Rupees in Lakhs)**

	Particulars	As at September 30, 2023	As at March 31, 2023
<b>I.</b>	<b>EQUITY AND LIABILITIES</b>		
<b>(1)</b>	<b>Shareholders' Funds</b>		
	(a) Share Capital	1766.86	1236.86
	(b) Reserve and surplus	987.35	101.47
<b>(2)</b>	<b>Minority Interest</b>	1.07	0.69
		<b>2755.27</b>	<b>1339.02</b>
<b>(3)</b>	<b>Non-current liabilities</b>		
	(a) Long-term borrowings	1780.36	1801.04
		<b>1780.36</b>	<b>1801.04</b>
<b>(4)</b>	<b>Current Liabilities</b>		
	(a) Short Term Borrowings	2037.89	2248.74
	(b) Trade Payables	781.83	677.60
	(i) Total outstanding dues of micro enterprises and small enterprises		
	(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	<b>0.00</b>	
	(c) Other Current Liabilities	85.40	118.01
	(d) Short-term Provisions	87.19	75.85
		<b>2992.31</b>	<b>3120.20</b>
	<b>TOTAL</b>	<b>7527.94</b>	<b>6260.25</b>
<b>II.</b>	<b>ASSETS</b>		
<b>(1)</b>	<b>Non Current Assets</b>		
	(a) Property, Plants & Equipment		
	(i) Tangible Assets	83.08	85.26
	(b) Non-Current Investments	0.00	57.34
	(c) Deferred tax assets (Net)	9.85	5.49
	(d) Long-term loans and advances	2.50	0.00
		<b>95.43</b>	<b>148.09</b>
<b>(2)</b>	<b>Current Assets</b>		
	(a) Inventories	3850.91	3268.61
	(b) Trade Receivables	2722.20	2187.07
	(c) Cash and Cash Equivalents	270.88	41.77
	(d) Short Term Loans and Advances	467.76	535.37
	(e) Other Current Assets	120.77	79.32
		<b>7432.51</b>	<b>6112.15</b>
	<b>TOTAL</b>	<b>7527.94</b>	<b>6260.25</b>

For and on behalf of the Board of Directors Mono Pharmacare Limited




Panilam S. Lakhatariya  
Chairman & Managing Director  
DIN: 07659275

Date: November 14, 2023

Ahmedabad

**MONO PHARMACARE LIMITED**

Registered Office: 1A, Krinkal Apartment, Opp. Mahalaxmi Temple, Paldi, Ahmedabad, Gujarat, Pin-380007

CIN: U24304GJ2022PLC136193

Website: www.monopharmacareltd.com

Email: info@monopharmacareltd.com

**Consolidated Statement of Unaudited Financial Results for the Half Year ended on September 30, 2023**

(Rupees in Lakhs)

	Particulars	For the Half Year ended on			For the year ended
		September 30, 2023	September 30, 2022	March 31, 2023	March 31, 2023
I	Revenue from operation	6653.12	2344.65	3502.99	5847.64
II	Other income	3.50	6.73	6.95	13.68
III	<b>Total Revenue ( I + II )</b>	<b>6656.62</b>	<b>2351.38</b>	<b>3509.94</b>	<b>5861.32</b>
IV	<b>Expenses</b>				
	Purchase of Traded Goods	6612.34	2415.85	5715.19	8131.03
	(Increase)/Decrease in Stock	-582.30	-217.76	-2579.49	-2797.24
	Employee Benefits Expenses	181.29	22.25	88.14	110.40
	Finance Cost	149.67	36.98	95.27	132.25
	Depreciation and Amortisation Cost				
	Other expenses	5.11	3.39	6.98	10.37
	<b>Total Expenses</b>	<b>6420.78</b>	<b>2286.87</b>	<b>3406.82</b>	<b>5693.69</b>
V	<b>Profit before tax Extraordinary and Exceptional Items ( III - IV )</b>	<b>235.85</b>	<b>64.51</b>	<b>103.12</b>	<b>167.63</b>
VI	Exceptional Items	0.00	0.00	0.00	0.00
VII	<b>Extraordinary Items And Tax ( V - VI )</b>				
	Prior Period Expenses	0.00	0.00	0.00	0.00
VIII	<b>Profit Before Tax</b>	<b>235.85</b>	<b>64.51</b>	<b>103.12</b>	<b>167.63</b>
IX	Tax Expenses				
	(1) Current Tax	53.30	5.00	44.54	49.54
	(2) Deferred Tax	-4.76	0.00	-5.28	-5.28
X	<b>Profit (Loss) for the Year</b>	<b>187.31</b>	<b>59.51</b>	<b>63.86</b>	<b>123.37</b>
XI	<b>Minority Interest</b>	<b>-0.77</b>	<b>0.00</b>	<b>-0.17</b>	<b>-0.17</b>
XII	<b>Profit/(Loss) for the year after Taxes and Minority Interest</b>	<b>186.54</b>	<b>59.51</b>	<b>63.69</b>	<b>123.20</b>
XIII	Earning per Equity share :				
	(1) Basic	1.43	0.87	1.37	1.79
	(2) Diluted	1.43	0.87	1.37	1.79

**Notes:**

1. The above results were reviewed and recommended by the Audit Committee, at its meeting held on 14th November, 2023 for approval by the Board and these results were approved and taken on record at the meeting of the Board of Directors of the Company held on that date. The Statutory Auditors have expressed an unqualified opinion.

2. The above consolidated financial result include Two subsidiaries firm M/s. Ahmedabad Municipal Corporation and M/s. Supal Distributors

3. The information presented above is extracted from the Audited Standalone Financial Statements for the financial year ended 31st March, 2023, and are prepared in accordance with the Accounting Standards as issued by the Institute of Chartered Accountants of India and as specified in Section 133 of the Companies Act, 2013 and the relevant rules thereof.

4. The information presented above is extracted from the Audited Standalone Financial Statements for the financial year ended 31st March, 2023, and are prepared in accordance with the Accounting Standards as issued by the Institute of Chartered Accountants of India and as specified in Section 133 of the Companies Act, 2013 and the relevant rules thereof.


5. The figures for the preceding half year ended on 31st March, 2023 as reported in these financial result, are the balancing figures between audited figures in respect of the full financial year ended on 31st March, 2023 and year to date unaudited figures upto the end of 30th September, 2022 based on the Management Certified Accounts which are not subjected to Limited Review by the Statutory Auditors. The Audited Figures for the year ended March 31, 2023 are derived from Audited Financial Statement of Mono Pharmacare Limited and M/s. Mono Chemist, a partnership firm which was converted in Mono Pharmacare Limited.

6. The above financial results are available on the website of the company i.e. www.monopharmacareltd.com and on the website of emerge platform of National Stock Exchange i.e. www.nseindia.com

7. Figures for previous half year/ year have been regrouped wherever necessary.

For and on behalf of the Board of Directors  
Mono Pharmacare Limited

*Panilam S. Lakhatariya*  
Panilam S. Lakhatariya  
Chairman & Managing Director



Date: November 14, 2023  
Ahmedabad

**MONO PHARMACARE LIMITED**

Registered Office: 1A, Krinkal Apartment, Opp. Mahalaxmi Temple, Paldi, Ahmedabad, Gujarat, Pin-380007

CIN: U24304GJ2022PLC136193

Website: www.monopharmacareltd.com

Email: info@monopharmacareltd.com

**Consolidated Statement of Unaudited Financial Results for the Half Year ended on September 30, 2023**


(Rupees in Lakhs)

	As at September 30, 2023	March 31, 2023
<b>Cash flow from operating activities</b>		
<b>Profit/(loss) before tax</b>	<b>235.85</b>	92.96
Non-cash adjustments to reconcile profit before tax to net cash flows		
Depreciation	5.11	4.74
Finance Cost	149.67	77.10
<b>Operating profit/(loss) before working capital changes</b>	<b>390.62</b>	<b>174.80</b>
<b>Movements in working capital:</b>		
Increase/(decrease) in trade payables	104.23	677.60
Increase/(decrease) in other current liabilities	-32.61	118.01
Increase/(decrease) in short term provision	11.34	75.85
Increase/(decrease) in short term borrowings	-210.85	2248.74
Decrease/(increase) in Inventories	-582.30	-3268.61
Decrease/(increase) in trade receivables	-535.13	-2187.07
Decrease/(increase) in short-term loans and advances	67.61	-535.37
Decrease/(increase) in other Current Assets	-41.45	-79.32
<b>Cash generated from Operations</b>	<b>-828.54</b>	<b>-2775.38</b>
Less: Direct taxes paid	-53.30	
<b>Net Cash from Operating Activities (A)</b>	<b>-881.84</b>	<b>-2775.38</b>
<b>Cash flows from investing activities</b>		
Sale/(Purchase) of Fixed Assets	-1.28	-86.30
Purchase of Investment	57.34	-57.34
<b>Net cash flow from/(used in) investing activities (B)</b>	<b>56.06</b>	<b>-143.64</b>
<b>Cash flow from financing activities</b>		
Acceptance / (Repayment) of Long Term Loan	-20.68	1801.04
Acceptance / (Repayment) of Long Term Loan	-2.50	
Increase in Share Capital	530.00	1236.86
Increase in Security Premium	697.74	
Finance Cost	-149.67	-77.10
<b>Net cash flow from/(used in) financing activities (C)</b>	<b>1054.89</b>	<b>2960.80</b>
Net increase/(decrease) in cash and cash equivalents (A+B+C)	229.11	41.77
Cash and cash equivalents at the beginning of the year	41.77	0.00
Cash and cash equivalents at the end of the year	270.88	41.77
<b>Net increase/(decrease) in cash and cash equivalents</b>	<b>229.11</b>	<b>41.77</b>

For and on behalf of the Board of Directors Mono Pharmacare Limited



Panilam S. Lakhatariya  
Chairman & Managing Director



Date: November 14, 2023  
Ahmedabad